Ivosidenib companion diagnostic - Agios Pharmaceuticals/Thermo Fisher Scientific

Drug Profile

Ivosidenib companion diagnostic - Agios Pharmaceuticals/Thermo Fisher Scientific

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thermo Fisher Scientific
  • Developer Agios Pharmaceuticals; Thermo Fisher Scientific
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cholangiocarcinoma

Most Recent Events

  • 18 May 2017 Thermo Fisher Scientific and Agios Pharmaceuticals enter research collaboration to develop Ivosidenib companion diagnostic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top